Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,654
archived clinical trials in
Cardiology

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Des Moines, IA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Des Moines, IA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Kansas City, KA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Kansas City, KA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Louisville, KY
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Louisville, KY
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
New Orleans, LA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
New Orleans, LA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
South Portland, ME
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
South Portland, ME
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Baltimore, MD
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Baltimore, MD
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Ayer, MA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Ayer, MA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Detroit, MI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Detroit, MI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Duluth, MN
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Duluth, MN
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
St Louis, MO
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
St Louis, MO
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Kalispell, MT
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Kalispell, MT
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Grand Island, NE
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Grand Island, NE
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Henderson, NV
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Henderson, NV
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Teaneck, NJ
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Teaneck, NJ
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Albuquerque, NM
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Albuquerque, NM
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Bronx, NY
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bronx, NY
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Asheville, NC
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Asheville, NC
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Bismarck, ND
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bismarck, ND
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Akron, OH
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Akron, OH
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Oklahoma City, OK
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Oklahoma City, OK
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Bend, OR
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bend, OR
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Allentown, PA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Allentown, PA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Pawtucket, RI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Pawtucket, RI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Anderson, SC
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Anderson, SC
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Sioux Falls, SD
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Sioux Falls, SD
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Chattanooga, TN
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Chattanooga, TN
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Houston, TX
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Houston, TX
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Annandale, VA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Annandale, VA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Bellingham, WA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Bellingham, WA
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Clinical Research Facility
mi
from
Beloit, WI
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications
A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients With Type 2 Diabetes
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Beloit, WI
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
Comparison of Prasugrel and Clopidogrel in Very Elderly and Non-Elderly Patients With Stable Coronary Artery Disease
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Very Elderly Versus Non-Elderly Aspirin-Treated Subjects With Stable Coronary Artery Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight With Coronary Artery Disease
A Pharmacokinetic and Pharmacodynamic Comparison of Prasugrel and Clopidogrel in Low Body Weight Versus Higher Body Weight Aspirin-Treated Subjects With Stable Coronary Artery Disease
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
Effect of Combined Estradiol and Drospirenone (E + DRSP) Versus Combined Estradiol and Medroxyprogesterone Acetate (E + MPA) Endothelial Function
Effect of Combined Estradiol and Drospirenone Treatment Versus Combined Estradiol and Medroxyprogesterone Acetate Treatment on Endothelial Function: A Crossover Study
Status: Archived
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Effect of Combined Estradiol and Drospirenone (E + DRSP) Versus Combined Estradiol and Medroxyprogesterone Acetate (E + MPA) Endothelial Function
Effect of Combined Estradiol and Drospirenone Treatment Versus Combined Estradiol and Medroxyprogesterone Acetate Treatment on Endothelial Function: A Crossover Study
Status: Archived
Updated: 1/1/1970
Brigham & Women's Hospital Women's Health Center
mi
from
Chestnut Hill, MA
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
University of Alabama - Burmingham
mi
from
Birmingham, AL
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
mi
from
Birmingham, AL
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Updated: 1/1/1970
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Veterans Affairs Medical Center - New York
mi
from
New York, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Updated: 1/1/1970
Veterans Affairs Medical Center - New York
mi
from
New York, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Albany Medical Center Hospital
mi
from
Albany, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Updated: 1/1/1970
Albany Medical Center Hospital
mi
from
Albany, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Montefiore Medical Center
mi
from
Bronx, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Updated: 1/1/1970
Montefiore Medical Center
mi
from
Bronx, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
New York Methodist Hospital
mi
from
Brooklyn, NY
Randomized Controlled, 3 Arm Clinical Trial Comparing EXXCEL Soft, FUSION and FUSION Bioline
Comparison of Safety and Primary Patency Between FUSIONTM Vascular Graft, FUSIONTM Vascular Graft With BiolinE, and EXXCELTM Soft ePTFE (FINEST)
Status: Archived
Updated: 1/1/1970
New York Methodist Hospital
mi
from
Brooklyn, NY
Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Natural History of CADASIL: Migraine, Diagnosis and Misdiagnosis
Status: Archived
New York University Langone Medical Center
mi
from
New York, NY
Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)
Natural History of CADASIL: Migraine, Diagnosis and Misdiagnosis
Status: Archived
Updated: 1/1/1970
New York University Langone Medical Center
mi
from
New York, NY
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
University of Vermont College of Medicine
mi
from
Burlington, VT
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Updated: 1/1/1970
University of Vermont College of Medicine
mi
from
Burlington, VT
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Clinical Research Facility
mi
from
Lansing, MI
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Lansing, MI
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Clinical Research Facility
mi
from
Minneapolis, MN
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Minneapolis, MN
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Clinical Research Facility
mi
from
Brooklyn, NY
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Brooklyn, NY
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Clinical Research Facility
mi
from
Muskogee, OK
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Muskogee, OK
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Clinical Research Facility
mi
from
Rapid City, SD
Clopidogrel to Prasugrel in Acute Coronary Syndrome (ACS) Patients
TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Rapid City, SD
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site
Status: Archived
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA
Percutaneous Coronary Intervention (PCI) Outcomes in Community Versus Tertiary Settings
A Randomized Trial to Compare Percutaneous Coronary Intervention Between Massachusetts Hospitals With Cardiac Surgery-On-Site and Community Hospitals Without Cardiac Surgery-On-Site
Status: Archived
Updated: 1/1/1970
Tufts Clinical Pharmacology Study Unit
mi
from
Boston, MA